Cerebrospinal fluid β‐amyloid and phospho‐tau biomarker interactions affecting brain structure in preclinical Alzheimer disease
Juan Fortea(Hospital de Sant Pau), Alberto Lleó(Hospital de Sant Pau), Eduard Vilaplana(Universitat Autònoma de Barcelona), Jordi Clarimón(Universitat Autònoma de Barcelona), Sofía Antón‐Aguirre(Universitat Autònoma de Barcelona), Jordi Pegueroles(Hospital de Sant Pau), Isabel Sala(Biomedical Research Networking Center on Neurodegenerative Diseases), María Carmona‐Iragui(Universitat Autònoma de Barcelona), Estrella Morenas(Universitat Autònoma de Barcelona), Daniel Alcolea(Hospital de Sant Pau), Rafael Blesa(Universitat Autònoma de Barcelona), Santiago Medrano(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), María‐Belén Sánchez‐Saudinós(Universitat Autònoma de Barcelona), Sofía González(University of Mendoza)
Cited by 148
Related Papers
New insights into the genetic etiology of Alzheimer’s disease and related dementias
|Nature Genetics|2022|2.5k
A multicentre validation study of the diagnostic value of plasma neurofilament light
|Nature Communications|2021|554
CSF biomarker variability in the Alzheimer's Association quality control program
|Alzheimer s & Dementia|2013|386
Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores
|Nature Communications|2021|345